







an Open Access Journal by MDPI

Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies

Guest Editors:

Dr. Mun-Ock Kim

Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea

Prof. Dr. Shazib Pervaiz

1. National University Cancer Science Institute, National University Health System (NUHS), Singapore, Singapore 2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

Deadline for manuscript submissions:

25 December 2024

Message from the Guest Editors

Dear Colleagues,

In this Special Issue of Cancers, titled "Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies", we aim to explore the multifaceted roles of unconventional cell death pathways in shaping CSC biology. Traditional apoptosis has been extensively studied, but emerging evidence suggests the involvement of non-apoptotic cell death modes like necroptosis, ferroptosis, and autophagy in modulating the fate of CSCs. Understanding how these alternative cell death mechanisms intersect with CSC regulation holds great promise for advancing our comprehension tumorigenesis.

We invite original research articles and reviews delving into the intricate connections between alternative cell death modes and CSC dynamics.

Join us in exploring cutting-edge research, aiming to unravel the complex relationships between alternative cell death modes and cancer stem cells, ultimately paving the way for novel therapeutic strategies.

Dr. Mun-Ock Kim Prof. Dr. Shazib Pervaiz Guest Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us